Conforming to the IPEC CoA Guide - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Conforming to the IPEC CoA Guide
Past IPEC-Americas excipient qualification committee chairs highlight changes to the IPEC guide on certificates of analysis for bulk excipients.


Pharmaceutical Technology
Volume 37, Issue 3, pp. 28-31

References

1. D. Schoneker, Changing the Supply-Chain Controls for Excipients –Part I: The IPEC-Americas Certificate of Analysis Guide for Bulk Pharmaceutical Excipients, Pharm.Tech. (June 2000).

2. IPEC-Americas, Excipient Master File Guide (2004), http://ipecamericas.org/.

3. IPEC-Americas and IPEC Europe, Excipient Pedigree Position Paper (2009), http://ipecamericas.org/.

4. IPEC-Americas and IPEC Europe, Excipient Stability Program Guide (2010), http://ipecamericas.org/.

5. IPEC-Americas and IPEC Europe, Good Distribution Practices Guide (2006), http://ipecamericas.org/.

6. IPEC-Americas, Good Distribution Practices Audit Guide (2011), http://ipecamericas.org/.

7. IPEC-Americas, IPEC Europe, and the PQG, Good Manufacturing Practices Audit Guide (2007), http://ipecamericas.org/.

8. IPEC-Americas, IPEC Europe, and the PQG, Good Manufacturing Practices Guide (2006), http://ipecamericas.org/.

9. IPEC-Americas and IPEC Europe, Qualification of Excipients for Use in Pharmaceuticals (2008), http://ipecamericas.org/.

10. IPEC-Americas and IPEC Europe, Quality Agreement Guide and Template (2009), http://ipecamericas.org/.

11. IPEC-Americas, Significant Change Guide (2009), http://ipecamericas.org/.

12. IPEC, International Pharmaceutical Excipient Council Glossary (2010), http://ipecamericas.org/.

13. A. Falk, PhD, Pharm.Tech. 34(3) (Mar. 2010).

14. B. Carlin et al., Pharm. Tech. 31 (9) (Sept. 2007).

15. PQG PS 9100:2002 Annex C Certificates of Analysis; WHO Technical Report Series, No. 902 & No. 908; UK Guidance on Certificates of Analysis (from Orange Guide).

16. Note: It is hoped that in the future, all excipient makers and excipient users will realize the benefits of establishing a long-term confidential disclosure agreement during the supplier qualification process.

17. USP, USP 35 General Notices, 5.40 Identity

18. 21 CFR 211.84(d)1

19. EU Legislation–Eudralex Vol 4: Good Manufacturing Practice Guidelines, Chapter 6 Quality Control, Annex 8 Sampling of Starting and Packaging Materials (2006).

Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect that of their employers.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here